Benefits
Anxiety with mild stimulating profile (Russian indication)
Russian approval for anxiety states. UNIQUE mechanism: GABA prodrug providing anxiolysis WITHOUT typical sedation due to niacin moiety's vasodilatory/stimulating effects. Mechanism: in CNS, cleaved to release GABA (anxiolytic) + niacin (vasodilator/possibly mild stimulant). Distinct from benzodiazepines (sedating) and from selank (peptide). Less rigorous evidence base than other Russian anxiolytics.
Cerebrovascular disease and cerebral circulation
Russian indication for cerebrovascular insufficiency and chronic cerebral ischemia. Mechanism: niacin component provides vasodilation enhancing cerebral blood flow. Used in older Russian clinical practice for elderly cognitive complaints related to cerebrovascular insufficiency. Limited rigorous clinical evidence outside Russian/CIS literature.
Mild depression / asthenic depression
Approved Russian indication for asthenic depression and chronic fatigue with depressive component. Combined GABA + niacin mechanism may provide both anxiolysis and mild activation. Limited rigorous Western RCT evidence.
GABA prodrug delivery (mechanism advantage)
Distinguishing pharmacological feature: Picamilon is GABA PRODRUG. Pure GABA cannot cross BBB efficiently. Niacin component provides lipophilicity for BBB penetration; once in CNS, amide bond cleaved by amidases to release GABA + nicotinic acid. Mechanism design rationale similar to phenibut (phenyl-GABA) but with niacin's additional vasodilatory and metabolic effects.
Migraine prophylaxis (limited Russian evidence)
Used in Russia for migraine prophylaxis based on theoretical cerebrovascular benefits. Limited rigorous evidence; not first-line treatment in any modern guidelines outside Russian clinical practice.
Mechanism of action
GABA prodrug — CNS amidase cleavage
Picamilon is N-nicotinoyl-GABA — synthetic conjugate cleaved in CNS by amidase enzymes to release: (1) GABA — inhibitory neurotransmitter providing anxiolytic effects via GABA-A receptor activation; (2) NICOTINIC ACID (niacin) — vasodilator with vitamin B3 activity. Dual delivery mechanism distinguishes from pure GABA-mimetic compounds.
Niacin vasodilation enhancing cerebral blood flow
Niacin component provides vasodilation — enhances cerebral blood flow and microcirculation. Mechanism for cerebrovascular insufficiency indications. Less prominent than direct GABA effects but contributes to overall pharmacology.
GABA-A receptor activation (post-cleavage)
Released GABA acts at GABA-A receptors providing anxiolysis. Less potent than direct GABA-A modulators (benzodiazepines) but more selective due to local CNS GABA release vs peripheral effects.
Modest BBB penetration via lipophilic conjugate
Amide-bonded niacin-GABA conjugate is more lipophilic than free GABA — crosses BBB. Once in CNS, cleaved to active components. Mechanism design similar to other prodrug strategies.
Clinical trials
Russian-language clinical studies in cerebrovascular insufficiency and cognitive disorders (multiple Russian publications, 1980s-1990s).
Russian patients with cerebrovascular insufficiency, chronic cerebral ischemia, asthenic disorders, anxiety states with autonomic features.
Russian clinical evidence supports use for cerebrovascular and anxiety conditions. Limited Western methodological scrutiny due to Russian-language predominance. Mechanism via GABA + niacin dual delivery. Approved Russian regulatory use since 1969 launch.
Russian preclinical/clinical pharmacology study (Silkina IV, Gan'shina TC, Seredin SB, Mirzoian RS 2005, Eksp Klin Farmakol 68(1):20-24, PMID 15786959).
Comparative pharmacology study of GABAergic mechanisms — afobazole (fabomotizole) and picamilon — in cerebrovascular and neuroprotective effects.
Picamilon demonstrated GABAergic cerebrovascular and neuroprotective effects. Mechanistic confirmation of GABA-mediated CNS effects via prodrug delivery. Foundational comparative evidence for picamilon's place in Russian neuropharmacology.
FDA Warning Letters issued November 2015 to multiple supplement companies marketing picamilon.
Supplement companies marketing picamilon as dietary supplement in US.
FDA DETERMINED picamilon NOT a legal dietary ingredient — declared synthetic drug rather than natural compound (vitamin, herb, or other DSHEA-eligible substance). Many companies removed picamilon products following warning letters. IMPORTANT REGULATORY HISTORY — distinguishes picamilon from other Russian peptides as NOT eligible for US dietary supplement marketing despite continued sales by some vendors. Demonstrates regulatory uncertainty for Russian-developed compounds in US market.